AB-248 is under clinical development by Asher Biotherapeutics and currently in Phase I for Non-Small Cell Lung Carcinoma. According to GlobalData, Phase I drugs for Non-Small Cell Lung Carcinoma have a 79% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how AB-248’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
AB-248 overview
AB-248 is under development for the treatment of locally advanced or metastatic solid tumors, including melanoma, renal cell carcinoma (RCC), non-small cell lung carcinoma (NSCLC) and squamous cell carcinoma of the head and neck (SCCHN). The drug candidate comprises mutant interleukin-2 polypeptides fused with antibody fragment. The drug candidate acts by targeting Interleukin 2 Receptor (IL2R). It is developed based on cis-targeting discovery platform. It is administered through intravenous route.
Asher Biotherapeutics overview
Asher Biotherapeutics., is a health care services provider that develops immunotherapy drugs designed to treat cancer. The company is headquartered in United States.
For a complete picture of AB-248’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
